These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25377046)

  • 1. Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis.
    Iurlo A; Cattaneo D; Gianelli U; Fermo E; Augello C; Cortelezzi A
    Ann Hematol; 2015 May; 94(5):881-2. PubMed ID: 25377046
    [No Abstract]   [Full Text] [Related]  

  • 2. JAK2V617F mutation is ubiquitously present in splanchnic vein thrombosis accompanying myeloproliferative syndromes.
    Kanellopoulou T; Alexopoulou A; Koskinas J
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1382-3. PubMed ID: 21569067
    [No Abstract]   [Full Text] [Related]  

  • 3. [Budd-Chiari syndrome and splanchnic vein thrombosis: masked myeloproliferative neoplasms and JAK2V617F].
    Fama A; Rago A; Gioiosa F; Marzano C; Latagliata R; Mammì C; Laganà C; D'Elia GM; Bizzoni L; Trasarti S; Ferretti A; Breccia M; Riggio O; Tafuri A
    Clin Ter; 2010; 161(2):169-71. PubMed ID: 20499034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calreticulin mutations and their importance in splanchnic vein thrombosis.
    Sekhar M; Patch D; Austen B; Howard J; Hart S
    Br J Haematol; 2016 Jul; 174(1):158-60. PubMed ID: 26358155
    [No Abstract]   [Full Text] [Related]  

  • 5. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
    Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
    Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
    Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM
    Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.
    Tondeur S; Boutruche S; Biron-Andréani C; Schved JF
    Thromb Haemost; 2009 Apr; 101(4):787-9. PubMed ID: 19350131
    [No Abstract]   [Full Text] [Related]  

  • 8. [Portal vein thrombosis as the main symptom of unclassified JAK2-positive myeloproliferative neoplasm--case report].
    Karakulska-Prystupiuk E; Gierej B; Paszkowska-Kowalewska M; Wilkowojska U; Jedrzejczak WW
    Pol Merkur Lekarski; 2012 Jul; 33(193):29-31. PubMed ID: 22993907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Portal vein thrombosis as the first sign of a primary myeloproliferative disorder: diagnostic interest of the V617F JAK-2 mutation. A report of 2 cases.
    de Suray N; Pranger D; Brenard R
    Acta Gastroenterol Belg; 2008; 71(1):39-41. PubMed ID: 18396750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation.
    Galati G; Gentilucci UV; Sansoni I; Spataro S; Di Matteo FM; Zardi EM; Grasso RF; Avvisati G; Afeltra A; Picardi A
    Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):233-6. PubMed ID: 19212214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis.
    Qi X; Hu F; Yang Z; Han G; Fan D
    Aliment Pharmacol Ther; 2011 Feb; 33(4):495-6; author reply 496-7. PubMed ID: 21235599
    [No Abstract]   [Full Text] [Related]  

  • 12. JAK2 V617F mutation associated with cerebral venous thrombosis: a report of five cases.
    Godeneche G; Gaillard N; Roy L; Mania A; Tondeur S; Chomel JC; Lavabre T; Arquizan C; Neau JP
    Cerebrovasc Dis; 2010 Jan; 29(2):206-9. PubMed ID: 20029191
    [No Abstract]   [Full Text] [Related]  

  • 13. Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies.
    Kiladjian JJ; Cassinat B
    Am J Hematol; 2023 May; 98(5):794-800. PubMed ID: 36869873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis.
    How J; Trinkaus KM; Oh ST
    Br J Haematol; 2018 Oct; 183(2):310-313. PubMed ID: 29048104
    [No Abstract]   [Full Text] [Related]  

  • 15. JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?
    Janssen HL; Leebeek FW
    Hepatology; 2006 Dec; 44(6):1391-3. PubMed ID: 17133464
    [No Abstract]   [Full Text] [Related]  

  • 16. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
    Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
    Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
    [No Abstract]   [Full Text] [Related]  

  • 17. [Any splanchnic vein thrombosis must make look for a forme fruste of myeloproliferative disorder].
    Casadevall N; Valla D
    Rev Prat; 2005 Oct; 55(15):1669-70. PubMed ID: 16334203
    [No Abstract]   [Full Text] [Related]  

  • 18. Occult myeloproliferative neoplasms: not so occult any more.
    Karam D; Iyer V; Agrawal B
    BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28559287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.
    Pardanani A; Lasho TL; Schwager S; Finke C; Hussein K; Pruthi RK; Tefferi A
    Leukemia; 2007 Aug; 21(8):1828-9. PubMed ID: 17460706
    [No Abstract]   [Full Text] [Related]  

  • 20. A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients.
    Xu N; Ding L; Yin C; Zhou X; Li L; Li Y; Lu Q; Liu XL
    Ann Hematol; 2015 May; 94(5):865-7. PubMed ID: 25366168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.